New mRNA vaccine combo aims to halt advanced melanoma
NCT ID NCT06961006
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can stop advanced melanoma from growing or spreading. About 160 people with stage III or IV melanoma that cannot be removed by surgery will receive either the vaccine plus pembrolizumab or a placebo plus pembrolizumab. The goal is to see if the combination helps people live longer without their cancer getting worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Blacktown Hospital ( Site 2001)
RECRUITINGBlacktown, New South Wales, 2148, Australia
-
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 2042)
RECRUITINGNice, Alpes-Maritimes, 06202, France
-
European Interbalkan Medical Center ( Site 2081)
RECRUITINGThessaloniki, 570 01, Greece
-
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 3021)
RECRUITINGMilan, Milano, 20133, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 3023)
RECRUITINGRoma, 00168, Italy
-
Fred Hutchinson Cancer Center ( Site 4041)
RECRUITINGSeattle, Washington, 98109, United States
-
General Hospital of Athens "Laiko" ( Site 2080)
RECRUITINGAthens, Attica, 115 27, Greece
-
Gustave Roussy ( Site 2040)
RECRUITINGVillejuif, Île-de-France Region, 94800, France
-
HaEmek Medical Center ( Site 3003)
RECRUITINGAfula, 1834111, Israel
-
Hadassah Medical Center ( Site 3001)
RECRUITINGJerusalem, 9112001, Israel
-
Harbour Cancer & Wellness ( Site 3040)
RECRUITINGAuckland, 1023, New Zealand
-
Highlands Oncology Group ( Site 4042)
RECRUITINGSpringdale, Arkansas, 72762, United States
-
Hospital Clínic Barcelona ( Site 3080)
RECRUITINGBarcelona, 08036, Spain
-
Hospital Universitari Vall d'Hebron ( Site 3081)
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 3082)
RECRUITINGMadrid, 28034, Spain
-
Hôpital Saint-Louis ( Site 2041)
RECRUITINGParis, Île-de-France Region, 75010, France
-
Inova Schar Cancer Institute ( Site 4046)
RECRUITINGFairfax, Virginia, 22031, United States
-
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 4000)
RECRUITINGPorto, 4200-072, Portugal
-
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 3020)
RECRUITINGNaples, 80131, Italy
-
Istituto Oncologico Veneto IRCCS ( Site 3022)
RECRUITINGPadova, 35128, Italy
-
John Theurer Cancer Center at Hackensack University Medical Center ( Site 4047)
RECRUITINGHackensack, New Jersey, 07601, United States
-
Melanoma Institute Australia ( Site 2000)
RECRUITINGWollstonecraft, New South Wales, 2065, Australia
-
Metropolitan Hospital ( Site 2082)
RECRUITINGAthens, Attica, 18547, Greece
-
NCT ( Site 2065)
RECRUITINGHeidelberg, Baden-Wurttemberg, 69120, Germany
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 3060)
RECRUITINGWarsaw, Masovian Voivodeship, 02-781, Poland
-
One Clinical Research ( Site 2002)
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Rabin Medical Center ( Site 3002)
RECRUITINGPetah Tikva, 4941492, Israel
-
Sheba Medical Center ( Site 3000)
RECRUITINGRamat Gan, 5265601, Israel
-
Sunnybrook Research Institute ( Site 2022)
RECRUITINGToronto, Ontario, M4N 3M5, Canada
-
UCSF Medical Center at Mission Bay ( Site 4044)
RECRUITINGSan Francisco, California, 94158, United States
-
Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 4002)
RECRUITINGLisbon, Lisbon District, 1449-005, Portugal
-
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 4001)
RECRUITINGLisbon, 1649-035, Portugal
-
Universitaetsklinikum Essen ( Site 2061)
RECRUITINGEssen, North Rhine-Westphalia, 45147, Germany
-
Universitaetsklinikum Hamburg-Eppendorf ( Site 2060)
RECRUITINGHamburg, 20251, Germany
-
Universitaetsklinikum Koeln ( Site 2064)
RECRUITINGCologne, North Rhine-Westphalia, 50937, Germany
-
Universitätsklinikum Frankfurt Goethe-Universität ( Site 2063)
RECRUITINGFrankfurt am Main, Hesse, 60590, Germany
-
Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 3061)
RECRUITINGPoznan, Greater Poland Voivodeship, 50 659, Poland
-
William Osler Health System (Brampton Civic Hospital) ( Site 2023)
RECRUITINGBrampton, Ontario, L6R 3J7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two immune boosters beat advanced melanoma?
- Can a new biologic drug shrink advanced melanoma tumors?
- Engineered immune cells take aim at Hard-to-Treat cancers
- Could a diabetes drug boost immunotherapy in advanced melanoma?
- Drug duo takes on rare head and neck tumors
- Experimental cancer therapy targets tough tumors with radioactive precision